Israeli-born offspring of Jewish immigrants of Middle Eastern origin have a lower incidence of multiple myeloma than those of European origin: a cohort study of 746 200 Israeli men followed from late adolescence

Abstract Differences in the prevalence of multiple myeloma across races have been observed, with a two- to three-fold greater prevalence in African Americans compared with Caucasians. Little is known about the incidence or prevalence of multiple myeloma in other populations. The association between father's country of origin and the incidence of multiple myeloma was examined in a nationwide population-based cohort. Health-related data on 746 200 16–19-year-old Jewish males examined between 1967 and 1998 were linked to the Israel National Cancer Registry to derive multiple myeloma incidence up to 2006. During 17 352 349 person-years of follow-up, 109 examinees developed plasma cell dyscrasias. Middle Eastern origin was protective compared to European origin (hazard ratio [HR] 0.39; 95% confidence interval [CI] 0.22–0.68; p = 0.001, adjusted for year of birth), and also when restricted to Israeli-born males (HR 0.44; 95% CI 0.24–0.82; p = 0.01). In conclusion, second-generation adolescents of Middle Eastern origin are at persistently lower risk of developing multiple myeloma compared to those of European origin, supporting a genetic component in the pathogenesis of multiple myeloma.

[1]  Thomas W. Mühleisen,et al.  Common variation at 3q26.2, 6p21.33, 17p11.2 and 22q13.1 influences multiple myeloma risk , 2013, Nature Genetics.

[2]  G. Roshandel,et al.  Epidemiology of leukemia and multiple myeloma in Golestan, Iran. , 2013, Asian Pacific journal of cancer prevention : APJCP.

[3]  H. Levine,et al.  Risk of germ cell testicular cancer according to origin: A migrant cohort study in 1,100,000 Israeli men , 2013, International journal of cancer.

[4]  H. Ostrer,et al.  The population genetics of the Jewish people , 2012, Human Genetics.

[5]  C. Vachon,et al.  Disparities in the prevalence, pathogenesis and progression of monoclonal gammopathy of undetermined significance and multiple myeloma between blacks and whites , 2012, Leukemia.

[6]  S. Rajkumar,et al.  Elucidating disparities across racial and ethnic groups in multiple myeloma patients , 2012, International Journal of Hematology.

[7]  Thomas W. Mühleisen,et al.  Common variation at 3p22.1 and 7p15.3 influences multiple myeloma risk , 2011, Nature Genetics.

[8]  S. Larsson,et al.  Body mass index and risk of multiple myeloma: a meta-analysis of prospective studies. , 2011, European journal of cancer.

[9]  E. Chang,et al.  Lymphoid Malignancies in U.S. Asians: Incidence Rate Differences by Birthplace and Acculturation , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[10]  K. McGlynn,et al.  Racial disparities in incidence and outcome in multiple myeloma: a population-based study. , 2010, Blood.

[11]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[12]  Saharon Rosset,et al.  The genome-wide structure of the Jewish people , 2010, Nature.

[13]  Leah E. Mechanic,et al.  Associations between anthropometry, cigarette smoking, alcohol consumption, and non-Hodgkin lymphoma in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. , 2010, American journal of epidemiology.

[14]  L. Bernstein,et al.  Anthropometric characteristics and multiple myeloma risk. , 2010, Epidemiology.

[15]  A. LaCroix,et al.  Intentional weight loss and risk of lymphohematopoietic cancers , 2010, Cancer Causes & Control.

[16]  U. Mellqvist,et al.  Patterns of hematologic malignancies and solid tumors among 37,838 first‐degree relatives of 13,896 patients with multiple myeloma in Sweden , 2009, International journal of cancer.

[17]  R. Goldbohm,et al.  Body mass index, height, and risk of lymphatic malignancies: a prospective cohort study. , 2009, American journal of epidemiology.

[18]  U. Mellqvist,et al.  Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden. , 2009, Blood.

[19]  B. Weiss,et al.  Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis , 2009, Leukemia.

[20]  R. Howard,et al.  A monoclonal gammopathy precedes multiple myeloma in most patients. , 2009, Blood.

[21]  R. Hayes,et al.  Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. , 2009, Blood.

[22]  L. Brown,et al.  Risk of multiple myeloma and monoclonal gammopathy of undetermined significance among white and black male United States veterans with prior autoimmune, infectious, inflammatory, and allergic disorders. , 2008, Blood.

[23]  M. Zwahlen,et al.  Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies , 2008, The Lancet.

[24]  L. Melton,et al.  Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana. , 2007, Mayo Clinic proceedings.

[25]  P. de Pablos Velasco,et al.  Obesity and cardiovascular disease , 2007, Public Health Nutrition.

[26]  L. Pantanowitz,et al.  Higher prevalence of monoclonal gammopathy of undetermined significance in African Americans than whites--the unknown role of underlying HIV infection. , 2006, Journal of the National Medical Association.

[27]  A. Dispenzieri,et al.  Prevalence of monoclonal gammopathy of undetermined significance. , 2006, The New England journal of medicine.

[28]  R. Hoover,et al.  Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. , 2005, Blood.

[29]  L. Hagmar,et al.  Allergic conditions and risk of hematological malignancies in adults: a cohort study , 2004, BMC public health.

[30]  D. R. Lewis,et al.  Multiple myeloma among blacks and Whites in the United States: the role of chronic antigenic stimulation , 1994, Cancer Causes & Control.

[31]  A. Olshan,et al.  Antigenic stimulation and the occurrence of multiple myeloma. , 1987, American journal of epidemiology.

[32]  J. Mclaughlin,et al.  A case-control study of multiple myeloma in whites: chronic antigenic stimulation, occupation, and drug use. , 1987, Cancer research.

[33]  Reuma Shapira,et al.  Multiple myeloma in Northern Israel, 1970–1979 , 1986, Cancer.

[34]  O. Cope,et al.  Multiple myeloma. , 1948, The New England journal of medicine.